JUBLINGREA Jubilant Ingrevia Q4 FY25 results (Jan–Mar 2025) and concall
Jubilant Ingrevia reported a strong Q4 FY25, driven by sustained growth in its Specialty Chemicals and Nutrition businesses, which saw significant margin expansion. Profitability was further boosted by cost reduction efforts, leading to a 153% YoY increase in PAT and an improved Net Debt-to-EBITDA ratio of 1.18x. While the Chemical Intermediates segment faced headwinds, the company is optimistic about a recovery and continues to invest in high-growth projects, including new CDMO opportunities and a recently commissioned Niacinamide plant.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 1,057 | 1,051 |
| EBITDA | 138 | 147 |
| Net profit | 69 | 74 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
